∙ To be eligible to participate in this trial, an adult individual must meet all the following criteria:

• Age 18 to 50 years at screening

• Male or female sex

• Informed consent form (ICF) signed and dated by the participant after reading the form and being advised of the risks and benefits of the trial in a language understood by the participant and before performance of any trial-specific procedures

• General good health, without clinically relevant medical illness, physical exam findings, or laboratory abnormalities, as determined by the investigator

• Body mass index (BMI) ≥18.5 and ≤35 (calculated as \[body weight in kilograms\] /\[body height in meters\] 2)

• Agreement by female participants of childbearing potential and male participants who are sexually active with a female partner of childbearing potential to use a highly effective method of birth control from at least 30 days prior to administration of the MVA-BN vaccine until 30 days after last vaccination

‣ Medically acceptable methods of contraception that may be used by the participant and/or partner include combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable), intrauterine device (IUD), intrauterine hormone releasing system (IUS), bilateral tubal occlusion, vasectomy, or abstinence (abstinence only acceptable if refraining from heterosexual intercourse during the entire period of 30 days prior to administration of the MVA-BN vaccine until 30 days after last vaccination).

⁃ Female participants or partners are not considered to be of childbearing potential if they are at least 1 year post-menopausal (amenorrhea \>12 months and follicle stimulating hormone according to local lab values) at screening.

• Willingness to comply with the requirements of the protocol, in the judgment of the investigator

∙ Pediatric Cohort

∙ To be eligible to participate in this trial, a child must meet all the following criteria:

• Age ≥2 and \<12 years at screening

• Male or female sex

• Informed consent form signed and dated by a parent/guardian after reading the form and being advised of the risks and benefits or the trial in a language understood by the parent/guardian and before performance of any trial-specific procedures

• Assent form signed and dated, for children required by local regulations

‣ provide consent ≥8 years of age enrolled at sites in Uganda

⁃ children deemed by the investigator and/or local regulations to be capable of assent in Democratic Republic of Congo

• General good health, without clinically relevant medical illness, physical exam findings, or laboratory abnormalities, as determined by the investigator

• Willingness of parent/guardian to comply with the requirements of the protocol, in the judgment of the investigator